Clinical Trials
17 trialsNCT06600321 2026-05-01
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Phase 1 Recruiting
NCT04134559 2026-02-24
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05438420 2026-02-24
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co., Ltd.
Phase 1/2 Active not recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT04374877 2025-11-10
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT05185739 2024-12-06
PRIMER-1
University College, London
Phase 2 Recruiting
NCT06492408 2024-07-09
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT03347292 2023-07-25
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Bayer
Phase 1 Completed
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed
NCT05339581 2022-04-27
iPLENTY-pvtt
RenJi Hospital
Phase NA Unknown
NCT05322187 2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3 Unknown
NCT03111732 2021-12-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown